Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CRT-SonR 9770 · 1 trial · 1 indication
Complication free rate of the SonR lead superior to 90 %
| Arm | Type | Description |
|---|---|---|
| CRT-SonR 9770 | EXPERIMENTAL | Active implantable defibrillator with ability to cardiac resynchronization therapy |
| Name | Type | Description |
|---|---|---|
| CRT-SonR 9770 | DEVICE | Active implantable defibrillator with capacity of cardiac resynchronization therapy |
Inclusion Criteria: * Patient eligible for implantation of a CRT 9770 device accordingly to the relevant currently-approved ACC/AHA/ESC guidelines or any relevant currently approved local guidelines for the implantation or replacement of triple-chamber ICD * Implanted with atrial SonR lead * Signed...
Top 20 of 31 competitors
CRT-SonR 9770 is an investigational device used for heart failure. It is a cardiac resynchronization therapy system that includes the SonR atrial lead and the Paradym RF device. It is currently in Phase 3 clinical development for this indication.
CRT-SonR 9770 is developed by LivaNova PLC, a company listed on the NASDAQ under the ticker symbol LIVN. The device is being studied for the treatment of heart failure.
CRT-SonR 9770 is in Phase 3 clinical development. It is an investigational device and is not yet approved for commercial use. A Phase 3 clinical trial has been completed to evaluate its safety and effectiveness in patients with heart failure.
CRT-SonR 9770 has one completed Phase 3 clinical trial, identified by the National Clinical Trial number NCT01169272. The trial, titled 'Clinical Evaluation Of The SonR Atrial Lead In Paradym RF Device,' enrolled 100 participants with heart failure in France.
CRT-SonR 9770 is a cardiac resynchronization therapy system that includes the SonR atrial lead and the Paradym RF device. The SonR atrial lead is a component of the CRT-SonR 9770 system, which is being evaluated for heart failure.